Sepsis Alliance and bioMérieux, Inc. Expand Partnership for 2017 to Promote Sepsis Awareness and Prevention

Durham, NC – San Diego, CA (May 10, 2017) – bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce that its U.S. affiliate, bioMérieux Inc. will be expanding its partnership with Sepsis Alliance. bioMérieux Inc. will serve as the 2017 National Sepsis Awareness and Education Title Sponsor, including sponsorship of Sepsis Alliance’s Sepsis ChallengeTM events.

Together, the two organizations will host a variety of events and collaborate on multiple initiatives throughout the year to raise public awareness about the risk of sepsis, and encourage the sharing of best practices for early sepsis detection and antibiotic stewardship among hospitals and healthcare professionals.

“Without question, bioMérieux is a partner that has given back in a meaningful, positive way to the healthcare community,” said Thomas Heymann, Executive Director of Sepsis Alliance. “We are very proud to work with an organization that shares our commitment to ending sepsis fatalities and injuries—so many of which are preventable with early detection and treatment.”

Sepsis Alliance and bioMérieux, Inc. will collaborate on several important resources aimed at educating health care professionals and the public about sepsis as a medical emergency, including a webinar series addressing various stages on the continuum of care for sepsis, a downloadable information guide series, and a new patient-focused sepsis video. In addition, bioMérieux will be the lead presenting sponsor on 2017 Sepsis ChallengeTM events, designed to raise awareness of sepsis among the general population. These resources will be instrumental in raising awareness about sepsis, which according to the 2016 Sepsis Alliance Annual Survey, just 55 percent of adults in the U.S. have ever heard of. bioMérieux is also a supporting sponsor of the 6th Annual Sepsis Hero Gala, an event held in New York City during Sepsis Awareness Month to honor people and organizations that have made a significant contribution to sepsis awareness and education among both the general public and healthcare professionals.

“Until a cure is found, the very best hope for sepsis patients is early detection,” said Stefan Willemsen, CEO of bioMérieux Inc. and Corporate Vice President Americas. “bioMérieux has been committed to the diagnosis of infectious diseases for more than 50 years and we are proud to partner with Sepsis Alliance in this public awareness campaign. This organization has been instrumental in making sepsis prevention and treatment a national priority.”

Visit www.biomerieux-usa.com to learn more about bioMérieux and for more information on Sepsis Alliance, please visit: www.sepsis.org.

About Sepsis Alliance

Sepsis Alliance is the leading nonprofit patient advocacy organization in North America. Sepsis Alliance's mission is to save lives by raising awareness of sepsis as a medical emergency. The organization hosts national and community events, distributes educational information, and promotes training and education on sepsis prevention and early recognition and treatment. Sepsis Alliance also supports sepsis survivors and family members with information about sepsis and Post Sepsis Syndrome, as well as a Faces of Sepsis community forum. The sepsis.org website receives more than 1.5 million visits each year. Sepsis Alliance, a 501(c)(3) charitable organization, is a GuideStar Gold Rated Charity. For more information, please visit www.sepsis.org

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2016, revenues reached €2,103 million, with more than 90% of international sales.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). U.S.
Website: www.biomerieux-usa.com
Sepsis Informational Website: www.sepsisknowfromday1.com

Media Relations Contacts:

bioMérieux
Tim Baker
Tel: 216-407-5354
timothy.baker@bioMérieux.com

Sepsis Alliance
Danielle Hoffpauir
Tel: 619-232-0300
dhoffpauir@sepsis.org